VU0155041 50 mg | 100.00%
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information Supplier PageVU0155041
Search Results
VU0155041 1 mg | 100.00%
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information Supplier PageVU0155041
VU0155041 10 mg | 100.00%
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information Supplier PageVU0155041
VU0155041 100 mg | 100.00%
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information Supplier PageRG14620 5 mg | 99.56%
TargetMol
RG14620
KS176 10 mg | 99.55%
TargetMol
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.
More Information Supplier PageKS176
KS176 25 mg | 99.55%
TargetMol
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.
More Information Supplier PageKS176
Ranitidine 10 mg | 99.10%
TargetMol
Ranitidine is a non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.
More Information Supplier PageRanitidine
Ranitidine 100 mg | 99.10%
TargetMol
Ranitidine is a non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.
More Information Supplier PageRanitidine
URB602 50 mg | 99.64%
TargetMol
URB602 is a specific monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL (IC50: 28±4 μM) through a noncompetitive mechanism.
More Information Supplier PageURB602
